BiotechTube
BridgeBio Pharma

BridgeBio Pharma

BBIOApproved
bridgebio.com

BridgeBio Pharma operates as a diversified biotech platform targeting genetic diseases through its innovative hub-and-spoke organizational model. The company has advanced multiple programs into Phase 3 trials, including acoramidis for transthyretin amyloidosis, encaleret for hypoparathyroidism, and infigratinib for achondroplasia. With over 2,000 patients enrolled in clinical trials globally and a pipeline consisting of 100% first-in-class or best-in-class therapies, BridgeBio has established itself as a leader in genetic medicine development.

Market Cap
$13.5B
+89.4% period
Pipeline
3
drug candidates
Patents
—
Publications
20
indexed

BBIO · Stock Price

USD 69.60+32.86 (+89.44%)

Historical price data

AI Company Overview

BridgeBio Pharma operates as a diversified biotech platform targeting genetic diseases through its innovative hub-and-spoke organizational model. The company has advanced multiple programs into Phase 3 trials, including acoramidis for transthyretin amyloidosis, encaleret for hypoparathyroidism, and infigratinib for achondroplasia. With over 2,000 patients enrolled in clinical trials globally and a pipeline consisting of 100% first-in-class or best-in-class therapies, BridgeBio has established itself as a leader in genetic medicine development.

Genetic DiseasesRare DiseasesNeuromuscular DisordersMetabolic DisordersSkeletal DysplasiasAmyloidosis

Technology Platform

Hub-and-spoke model focused on genetic diseases with clear biological drivers, utilizing small molecule approaches to target mutations, missing enzymes, and misfolded proteins at their root cause.

Pipeline

3
3 drugs in pipeline
DrugIndicationStageWatch
BBP-398 + sotorasibSolid Tumor, AdultPhase 1
BBP-398 (Formerly known as IACS-15509)Tumor, SolidPhase 1
BBP-398 with nivolumabNon Small Cell Lung CancerPhase 1

Funding History

4
Total raised:$868.5M
PIPE$250MDec 15, 2020
IPO$348.5MJun 27, 2019
Series B$135MJun 15, 2017
Series A$135MJun 15, 2015

FDA Approved Drugs

1
ATTRUBYNDANov 22, 2024

Opportunities

Multiple late-stage programs approaching regulatory submissions with potential for first-in-class approvals in large underserved rare disease markets.
The hub-and-spoke model enables efficient scaling across additional genetic disease indications with strong academic partnerships providing early-stage pipeline opportunities.

Risk Factors

Clinical development risks across multiple simultaneous Phase 3 programs, regulatory approval uncertainty for rare disease indications, and dependence on successful commercialization in niche markets with potential reimbursement challenges.

Competitive Landscape

BridgeBio operates in the competitive rare disease space but differentiates through its unique hub-and-spoke organizational model and focus on genetic diseases with clear biological rationale. The company's 100% first-in-class or best-in-class pipeline positioning provides competitive advantages in underserved markets.